Effects of testosterone on antioxidant systems in male secondary hypogonadism

Journal of Andrology

Volumn 29, Issue 6, 2008, Pages 622-629

  Mancini, Antonio ^a,c   Leone, Erika ^a   Festa, Roberto ^a   Grande, Giuseppe ^a   Silvestrini, Andrea ^a   De Marinis, Laura ^a   Pontecorvi, Alfredo ^a   Maira, Giulio ^a   Littarru, Gian Paolo ^b   Meucci, Elisabetta ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c NONE   (Italy)

Author keywords

Androgen; Coenzyme Q10; Oxidative stress; Total antioxidant capacity

Indexed keywords

CHROMOGEN 2,2' AZINOBIS 3 ETHYLBENZOTHIAZOLINE 6 SULFONANTE; CHROMOGENIC SUBSTRATE; TESTOSTERONE; UBIDECARENONE; UNCLASSIFIED DRUG;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; MALE; OPERATION DURATION; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECTROSCOPY; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT;

ADULT; ANTIOXIDANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYPOGONADISM; HYPOPITUITARISM; MALE; MIDDLE AGED; OXIDATIVE STRESS; TESTOSTERONE; UBIQUINONE;

EID: 56249115218     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.107.004838     Document Type: Article

References (56)

1. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis. A study of castrated, cholesterol fed rabbits. Circ Res. 1999;84:813-819.
2. Avres S, Tang M, Subbiah MT. Estradiol-17beta as an antioxidant: some distinct features when compared with common fat-soluble antioxidants. J Lab Clin Med. 1996;128(4):367-375.
3. Bartoz G. Total antioxidant capacity. Adv Clin Chem. 2003;37: 219-292.
4. 10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Mol Aspects Med. 1997;18:169-179.
5. Brown-Borg HM, Bode AM, Bartke A. Antioxidative mechanisms and plasma growth hormone levels: potential relationship in the aging process. Endocrine. 1999;11(1):41-48.
6. Channer KS, Jones TH. Cardiovascular effects of testosterone: implications of the "male menopause"? Heart. 2003; 89:121-122.
7. Chevion S, Chevion M. Antioxidant status and human health. Use of cyclic voltammetry for the evaluation of the antioxidant capacity of plasma and of edible plants. Ann N Y Acad Sci. 2000;899:308-325.
8. Crane P, Frederick L. Biochemical functions of coenzyme Q10. J Am Coll Nutr. 2001;20:591-598.
9. Daughaday WH, Mariz IK, Blethen SL. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab. 1980;51:781-788.
10. Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ. Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol. 2001;281:1720-1727.
11. Demirbag R, Yilmaz R, Erel O. The association of total antioxidant capacity with sex hormones. Scand Cardiovasc J. 2005;39:172-176.
12. English K, Steeds RP, Jones TH, Channer KS. Testosterone and ischaemic heart disease: is there a link? QJM. 1997;90:787-791.
13. English KM, Jones RD, Jones TH, Morice AH, Channer KS. Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res. 2001;33: 645-652.
14. English KM, Jones RD, Jones TH, Morice AH, Channer KS. Testosterone acts as a coronary vasodilator by a calcium channel antagonist action. J Endocrinol Invest. 2002;25:455-458.
15. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of testosterone than those with normal coronary angiograms. Eur Heart J. 2000;21:890-894.
16. Erel O. A novel-automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004; 37:112-119.
17. 10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCO-2 cells. Int J Biochem Cell Biol. 2005;37:1208-1218.
18. Haffner SM, Karhapää P, Mykkänem L, Laakso M. Insulin resistance, body fat distribution, and sex hormone in men. Diabetes. 1994a;43:212-219.
19. Haffner SM, Valdez RA, Mykkanem L, Stern MP, Katz MS. Decreased testosterone and dehydroepiandrosterone sulphate concentrations are associated with increased insulin and glucose concentrations in non-diabetic men. Metabolism. 1994b;43:599-603.
20. Horrum MA, Tobin RB, Ecklund RE. Thyroxine-induced changes in rat liver mitochondrial ubiquinone. Biochem Biophys Res Commun. 1986;138(1):381-386.
21. Ikeda S, Hamada N, Morii H, Inaba M, Yamakawa J. Serum and tissue coenzyme Q9 in rats with thyroid dysfunctions. Horm Metab Res. 1984;16:585-588.
22. Jones RD, Pugh PJ, Jones TH, Channer KS. The vaso-dilatory action of testosterone - a potassium channel opening or a calcium channel antagonistic action. Br J Pharmacol. 2003a;138:733-744.
23. 2α-mediated increase in intracellular calcium in A7r5 aortic smooth muscle cells: evidence of an antagonistic action upon store operated calcium channels. J Endocrinol. 2003b;178:381-393.
24. Kedziora-Kornatowska K, Bartosz M, Mussur M, Zasłonka J, Kedziora J, Bartosz G. The total antioxidant capacity of blood plasma during cardiovasculary bypass surgery in patients with coronary heart disease. Cell Mol Biol Lett. 2003;8:973-977.
25. Keyes WG, Wilcox HG, Heimberg M. Formation of the very low density lipoprotein and metabolism of [1-14C]-oleate by perfused livers from rats treated with triiodothyronine or propylthiouracil. Metabolism. 1981;30:135-146.
26. 10. Ann Neurol. 1997;41:160-165.
27. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006; 91:843-850.
28. Larsen PR, Davies TF. Hypothyroidism and thyroiditis. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology. 10th ed. Philadelphia: Saunders; 2003: 423-455.
29. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24(3):313-340.
30. Mancini A, Bianchi A, Fusco A, Sacco E, Leone E, Tilaro L, Porcelli T, Giampietro A, Principi F, De Marinis L, Littarru GP. Coenzyme Q10 evaluation in pituitary-adrenal axis disease: preliminary data. Biofactors. 2005;25:197-199.
31. Mancini A, Calabrò F, Fiumara C, Conte G, Oradei A, Lippa S, De Marinis L, Littarru GP. Plasma coenzyme Q10 determination in acromegaly. Exp Clin Endocrinol Life Sci Adv. 1992;11:55-60.
32. Mancini A, De Marinis L, Calabrò F, Fiumara C, Goglia A, Sofo L, Lippa S, Oradei A, Rabitti C, Littarru GP. Physiopathological relevance of coenzyme Q10 in thyroid disorders: CoQ10 concentrations in normal and diseased human thyroid tissue. In: Folkers K, Littarru GP, Yamagami T, eds. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier; 1991: 441-448.
33. Mancini A, De Marinis L, Calabrò F, Sciuto R, Oradei A, Lippa S, Sandric S, Littarru GP, Barbarino A. Evaluation of metabolic status in amiodarone-induced thyroid disorders: plasma coenzyme Q10 determination. J Endocrinol. Invest. 1989;12: 511-516.
34. Mancini A, Milardi D, Bianchi A, Meucci E, Pontecorvi A, De Marinis L. Hormonal regulation of total antioxidant capacity in seminal plasma. In: Kim S, Grootegoed JA, Chemes HE, eds. Proceedings of the 8th International Congress of Andrology. Seoul, Korea, Free Papers. Bologna: Medimond; 2005:59-62.
35. Massafra C, De Felice C, Gioia D, Buonocore G. Variations in erythrocyte antioxidant glutathione peroxidase activity during the menstrual cycle. Clin Endocrinol. 1998;49:63-67.
36. Massafra C, Gioia D, De Felice C, Picciolini E, De Leo V, Bonifazi M, Bernabei A. Effects of estrogens and androgens on erythrocyte antioxidant superoxide dismutase, catalase and glutathione peroxidase activities during the menstrual cycle. J Endocrinol. 2000;167: 447-452.
37. Mendis-Handagama SM, Siril Ariyaratne HB. Leydig cells, thyroid hormones and steroidogenesis. Indian J Exp Biol. 2005;43(11): 939-962.
38. Meucci E, Milardi D, Mordente A, Martorana GE, Giacchi E, De Mannis L, Mancini A. Total antioxidant capacity in patients with varicoceles. Fertil Steril. 2003;79(3):1577-1583.
39. Mosca F, Fattorini D, Bompadre S, Littarru GP. Assay of coenzyme Q(10) in plasma by a single dilution step. Anal Biochem. 2002;305: 49-54.
40. Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FCW. Testosterone replacement therapy: current trends and future directions. Hum Reprod. 2004;10: 409-419.
41. Olson RE, Rudney H. Biosynthesis of ubiquinone. Vitam Horm. 1983;40:1-43.
42. Prior RL, Cao G. In vivo total antioxidant capacity: comparison of different analytical methods. Free Radic Biol Med. 1999;27: 1173-1181.
43. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol. 1994;234:279-293.
44. Rosano GMC, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, Della Monica PL, Bonfigli B, Volpe M, Chierchia SL. Acute anti-ischaemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99:1666-1670.
45. Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, Papoz L. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom study. Diabetologia. 1992;35:173-177.
46. 10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem. 2003;246:75-82.
47. 10 inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol. 2001;21:585-593.
48. 10 ratio as a possible marker of increased risk for atherosclerosis. Biofactors. 1999;9:231-240.
49. Toni R, Della Casa C, Castorina S, Cocchi D, Celotti F. Effects of hypothyroidism and endocrine disruptor-dependent non-thyroidal illness syndrome on the GnRH-gonadotroph axis of the adult male rat. J Endocrinol Invest. 2005;28(11 suppl proc):20-27.
50. Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab. 1972;34: 730-735.
51. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672.
52. Von Eckardstein A, Wu FCW. Testosterone and cardiovascular disease. In: Nieschlag E, Behre HM, eds. Testosterone. Action, Deficiency, Substitution. 3rd ed. Cambridge: University Press; 2004:297-331.
53. Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischaemia in men with coronary artery disease. Am J Cardiol. 1999a;83:437-439.
54. Webb CM, McNeill JG, Hayward CS, De Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999b;100:1690-1696.
55. Wu FCW, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev. 2003;24(2):183-217.
56. 10 concentrations in coronary artery disease. Clin Biochem. 2004; 37:706-709.